Stanley B Katz

US Patent:

6482856, Nov 19, 2002

Filed:

Jul 7, 1999

Appl. No.:

09/348698

Inventors:

Stanley E. Katz - Milltown NJ

Assignee:

Cellular Sciences, Inc. - Flemington NJ

International Classification:

A01N 3700

US Classification:

514557, 514558, 514559, 514560, 514826, 424 45

Abstract:

A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.

US Patent:

6623723, Sep 23, 2003

Filed:

Aug 21, 2001

Appl. No.:

09/933981

Inventors:

Stanley E. Katz - Milltown NJ

Assignee:

Cellular Sciences Inc. - Flemington NJ

International Classification:

A61K 912

US Classification:

424 46, 424 45, 514 54, 514557, 514625, 514826, 12820014, 12820315

Abstract:

The present invention is directed to a method for treating bronchial constriction in mammals. The method comprises contacting mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to produce bronchial dilation. The present invention is also directed to a method for treating airway disease in mammals. The method comprises contacting mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in an amount from about 0. 0001 millimoles to about 0. 005 millimoles. The present invention is further directed to a method for treating airway disease in mammals. The method comprises contacting the mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to prevent bronchial spasm.

US Patent:

20020006961, Jan 17, 2002

Filed:

May 1, 2001

Appl. No.:

09/846722

Inventors:

Stanley Katz - Milltown NJ, US
Alain Martin - Ringoes NJ, US

International Classification:

A61K031/19
A61K031/16

US Classification:

514/625000, 514/557000

Abstract:

A method for treating the disease state in mammals caused by mammalian nasal and sinus cells involved in the inflammatory response is disclosed. Mammalian nasal and sinus cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.

US Patent:

20060247308, Nov 2, 2006

Filed:

Jun 30, 2006

Appl. No.:

11/478822

Inventors:

Stanley Katz - Milltown NJ, US
Alain Martin - Ringoes NJ, US

International Classification:

A61K 31/28
A61K 31/19
A61K 31/198

US Classification:

514492000, 514562000, 514563000, 514557000

Abstract:

A method for treating the disease state in mammals caused by mammalian nasal and sinus cells involved in the inflammatory response is disclosed. Mammalian nasal and sinus cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.

US Patent:

59394595, Aug 17, 1999

Filed:

Mar 18, 1998

Appl. No.:

9/040679

Inventors:

Stanley E. Katz - Milltown NJ

Assignee:

Cellular Sciences Inc. - Flemington NJ

International Classification:

A61K 3116
A61K 3119
A61K 3122

US Classification:

514625

Abstract:

A method for treating emphysema and other disease states in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.

US Patent:

57983887, Aug 25, 1998

Filed:

Sep 6, 1996

Appl. No.:

8/709043

Inventors:

Stanley E. Katz - Milltown NJ

Assignee:

Cellular Sciences, Inc. - Flemington NJ

International Classification:

A61K 3119
A61K 3122

US Classification:

514557

Abstract:

A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.

US Patent:

59523840, Sep 14, 1999

Filed:

Mar 18, 1998

Appl. No.:

9/040678

Inventors:

Stanley E. Katz - Milltown NJ

Assignee:

Cellular Sciences, Inc. - Flemington NJ

International Classification:

A61K 3119
A61K 3122

US Classification:

514625

Abstract:

A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Composition, for reducing and treating undesired inflammatory response are also disclosed.